United Therapeutics (NASDAQ:UTHR) Given New $701.00 Price Target at Royal Bank Of Canada

United Therapeutics (NASDAQ:UTHR) had its price target cut by Royal Bank Of Canada from $707.00 to $701.00 in a research report report published on Thursday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company set a $735.00 target price on United Therapeutics and gave the company an “overweight” rating in a research note on Thursday. Finally, Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $569.18 on Thursday. The business has a 50 day moving average of $550.17 and a 200 day moving average of $501.37. The company has a market capitalization of $24.05 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 1.70 and a beta of 0.60. United Therapeutics has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the firm posted $6.63 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that United Therapeutics will post 27.97 EPS for the current year.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 485,155 shares of company stock worth $266,370,949 over the last three months. Insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. AE Wealth Management LLC boosted its position in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC boosted its position in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new position in United Therapeutics in the third quarter worth about $444,000. Tobam boosted its position in United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after purchasing an additional 4,953 shares during the last quarter. Finally, Sawgrass Asset Management LLC purchased a new position in United Therapeutics in the third quarter worth about $11,460,000. 94.08% of the stock is owned by institutional investors.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors focused on product/catalyst upside — market reaction was supported by management highlighting positive Tyvaso data in IPF and continued optimism around ralinepag’s blockbuster potential, which many say could drive significant future growth. UTHR Q1 Earnings Miss — Shares Jump on Strong Outlook
• Positive Sentiment: Partnership expansion with MannKind around DPI technology may improve delivery/manufacturing optionality and was reported to boost MannKind’s stock — a potential operational positive for United Therapeutics’ inhaled product ambitions. MannKind Stock Surges on Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $707 to $701 but retained an “outperform” rating, leaving a sizable implied upside from current levels; this is broadly supportive but not catalytic. RBC Lowers PT to $701
• Negative Sentiment: Q1 financials missed consensus: EPS of $5.82 vs. estimates near $7.00 and revenue $781.5M vs. ~$797M — revenue declined ~2% YoY. The miss can pressure short-term sentiment despite healthy margins. Q1 2026 Financial Results
• Negative Sentiment: Significant insider selling: CEO Martine Rothblatt sold 9,500 shares (~19% reduction in her disclosed holding) and EVP Paul Mahon sold 8,300 shares (~15.5% reduction). Large, contemporaneous insider reductions can weigh on sentiment, especially after an earnings miss. Rothblatt SEC Filing Mahon SEC Filing

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.